New Data Demonstrate The Cost-Effectiveness Of Bendamustine In The Treatment Of Chronic Lymphocytic Leukaemia (CLL)

Published Jun 17, 2012
Cambridge, UK – New data published in Value in Health, the official journal of the International Society for Pharmacoeconomics and outcomes Research (ISPOR) show that bendamustine represents good value for first-line treatment of advanced chronic lymphocytic leukaemia (CLL) in patients unsuitable for fludarabine-based treatment. The study, “Bendamustine Versus Chlorambucil For The First-Line Treatment Of Chronic Lymphocytic Leukaemia In England And Wales: A Cost-Utility Analysis,” evaluated the cost-effectiveness of bendamustine against the current standard of care in first-line treatment of patients with advanced CLL unsuitable for fludarabine-based treatment (the current ‘gold standard’ in the UK). Results of the analysis showed an incremental cost-effectiveness ratio (ICER) of GBP11,960 per quality adjusted life year, that is well below the threshold of GBP20,000 – 30,000 commonly applied in the UK. The study, which was funded by Napp Pharmaceuticals Limited, formed part of a successful health technology appraisal for the National Institute for Health and Clinical Excellence (NICE) in the UK, with the evidence review group report describing the economic model as “high quality”. CLL is the most common leukaemia amongst adults in industrialised countries, and accounts for 40% of all leukaemia cases in those aged over 65 years. Professor Dr. Wolfgang Knauf, Consultant Haematologist, Frankfurt, Germany, said: “I am delighted to hear that not only was bendamustine of clinical benefit over chlorambucil but bendamustine was also cost-effective in an increasingly cost conscious world.”

Value in Health (ISSN 1098-3015) publishes papers, concepts, and ideas that advance the field of pharmacoeconomics and outcomes research as well as policy papers to help health care leaders make evidence-based decisions. The journal is published bi-monthly and has over 8,000 subscribers (clinicians, decision makers, and researchers worldwide).

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a nonprofit, international, educational and scientific organization that strives to increase the efficiency, effectiveness, and fairness of health care resource use to improve health.

For more information:

Related Stories

Measuring What Matters: Broadening the Scope of Health Economics Evaluation to Incorporate Well-Being

Jul 9, 2024

ISPOR announced the publication of a special themed section of research papers in Value in Health that offer insights into facets of economic evaluation aimed to incorporate well-being into decision making.

Confronting the Backlash Against QALYs: Key Insights From Leading Health Economists

Jun 18, 2024

ISPOR announced the publication of a collection of papers that examine the long-standing debate surrounding the use of quality-adjusted life years (QALYs) and alternative measures in healthcare decision making.

ISPOR Good Practices Report Offers Guidance for Using Real-World Data From EHRs in Health Technology Assessments

Jun 17, 2024

ISPOR announced the publication of an ISPOR Good Practices Report that proposes a framework for assessing the suitability of electronic health records data for use in health technology assessments. The report, “Assessing Real-World Data from Electronic Health Records for Health Technology Assessment: The SUITABILITY Checklist: A Good Practices Report of an ISPOR Task Force” was published in the June 2024 issue of Value in Health.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on Update my browser now